Tristel Revenue Rose 16% to £17.5 million in 2022

Tristel, a company based in Snailwell, Cambridgeshire, manufactures infection control solutions using patented chlorine dioxide technology. They have recently reported a rise in revenue of 16% and a 16x growth in earnings before interest, taxes, depreciation, and amortisation.

The company’s main line of business is selling chlorine dioxide chemicals to hospital environments for use as a sporicidal agent marketed as part of ‘The Cache Collection’ and decontaminating medical equipment under the ‘Tristel’ brand.

In the last year, sales grew to £17.5 million, and Tristel transformed a pretax deficit of £1.2 million into a profit of £2.4 million.

After distributing dividend payments of £3.3 million, with one payment alone totalling an enormous £1.4 million, Tristel can boast no debt and a healthy £8.4 million in cash.

According to Chief Executive, Paul Swinney, Tristel is now prepared to capitalise on additional growth as it expands across to North America.

He explained that they are “delighted to have increased sales by 16% on the first half of last year – above our long-term target for revenue growth.”

“In all regions the level of diagnostic examinations utilising our products” has grown compared to before the Covid 19 pandemic.

“We have now entered the North American market. The growth prospects are stronger than ever, and we look to the future with confidence.”